Heerlen, NL, 02 Nov 2021 07:00 CET
|in € million||Jan-Sep 2021||Jan-Sep 2020||% Change||Volume||Price/mix||FX||Other|
|Adjusted EBITDA margin||20.2%||19.0%|
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: “Good end-user demand throughout the quarter continued the positive momentum of both our Nutrition and Materials businesses. We have delivered another strong period by actively managing the volatile global supply chain dynamics and therefore ensuring we remain able to meet the needs of our customers within the current challenging environment.
During the quarter we also provided an update on the acceleration of our strategy as a purpose-led, performance-driven leader in Health, Nutrition & Bioscience, including our new food system commitments.”
For the full year, DSM continues to expect an Adjusted EBITDA increase in Nutrition at the upper end of its mid-term strategic ambition of high single digit growth. Together with the strong performance in Materials, DSM expects an Adjusted EBITDA growth rate for the Group in the mid-teens, with a continued good Adjusted Net Operating Free Cash Flow.
The complete version of this press release can be found here.
1) Adjusted EBITDA is an Alternative Performance Measure (APM) that reflects results from usual operations. Organic sales growth is the total impact of volume and price/mix. Adjusted Net Operating Free Cash Flow is the cash flow from operating activities, corrected for the cash flow of the APM adjustments, minus the cash flow of capital expenditures and drawing rights.
2) Results and KPIs throughout this press release reflect continued operations, excluding the Resins & Functional Materials and associated businesses which were classified as ‘held for sale’ in September 2020. The sale was finalized on 1 April 2021.